Gaia Novarino is a full professor of neuroscience at IST Austria and one of three vice presidents. Her focus is on genetics and molecular mechanisms of neurodevelopmental disorders. She has published groundbreaking studies in prestigious journals such as Science, Cell, Nature Neuroscience. She was one of the first to describe a genetic form of autism and epilepsy that can be treated and reversed through nutritional supplementation. She is a Simons Foundation SFARI investigator, ERC Starting and Consolidator grant holder (2017-2022, 2023-2028), FENS Kavli Network Fellow, and recipient of the Boehringer Ingelheim FENS Research Award. She has an intrinsic motivation and enthusiasm to bring excellent and novel research developments to benefit patients, with a keen interest in translational medicine and entrepreneurship. Gaia Novarino is a co-founder and scientific advisor of Neurolentech. Her national and international network among scientists and clinicians will be important to Neurolentech´s lasting success. She, also, co- founded Solgate, a pre-clinical drug development company focused on SLC transporters with currently ~20 employees.

Christoph Bock is a Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and Professor of [Bio]Medical Informatics at the Medical University of Vienna. His research combines experimental biology (high-throughput sequencing, epigenetics, CRISPR screening, synthetic biology) with computational methods (bioinformatics, machine learning, artificial intelligence) – for cancer, immunology, and precision medicine. Before coming to Vienna, he was a postdoc at the Broad Institute of MIT and Harvard (2008-2011) and a PhD student at the Max Planck Institute for Informatics (2004-2008). Christoph Bock is also a informatics group leader at the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD), coordinator of an EU Horizon 2020 project that contributes single-cell sequencing of human organoids to the Human Cell Atlas, and fellow of the European Lab for Learning and Intelligent Systems (ELLIS). He has received important research awards, including the Otto Hahn Medal of the Max Planck Society (2009), an ERC Starting Grant (2016-2021), an ERC Consolidator Grant (2021-2026), and the Overton Prize of the International Society for Computational Biology (2017). He has been included in the global list of “Highly Cited Researchers” by Clarivate Analytics (ISI Web of Science) in each year since 2019. He co-founded Myllia Biotechnology, a Vienna-based startup company that develops and applies single-cell methods for high- throughput biology and drug discovery (currently ~40 employees). Christoph Bock is a co-founder and scientific advisor of Neurolentech. He contributes key expertise in high-throughput technology, bioinformatics and machine learning, as well as a strong global network in the field of single-cell biology. Beyond his computational research on human diseases, Christoph runs a sequencing core facility and engages in enhancing “genetic literacy” in the Austrian population through teaching, outreach and advocacy (e.g., https://nature.com/articles/537009a).

Nick Lynch is an expert in data management for biotechs and biopharma. His background in data and informatics leaderships including AstraZeneca & Xenova Discovery, bring a wealth of knowledge and experience to the team. He has made significant contributions to the fields of Health & Life Sciences through his company Curlew Research, which specializes in informatics and data strategy consulting for biopharma and biotechs. In addition to his entrepreneurial achievements, Dr. Lynch was a co-founder of the Pistoia Alliance and CTO of OpenPHACTS (an IHI funded project). His extensive background and deep industry insights make him an invaluable addition to our team.

Peter Simpson has a background in Neuroscience biology and imaging, and was a director of Discovery Services at AstraZeneca before broadening his reach to numerous biotech startup companies through his directorship at N8 Research Partnership and later his position as Chief Scientific Officer at the Medicines Discovery Catapult in the UK. With prices like the BioNow Award, OBN Award, and 'Pride of Macclesfield' Award for contributions to life sciences and Covid national response as well as a broad experience as a senior leader in big pharma, open innovation partnerships, academic collaborations, successful major grant writing, and leading the strategy for the UK's national center of drug discovery excellence, Dr. Simpson will be leading the team into the world of drug discovery.

Prof. Rubeis is a bioethicist with a focus on digital health technologies and molecular medicine. His research topics include the ethics of big data and AI-applications in healthcare as well as ethical implications of genome editing. Prof. Rubeis is head of the Division Biomedical and Public Health Ethics at the Karl Landsteiner University of Health Sciences. He published several dozen papers in international high-impact journals and lead research projects funded by key players in the research field, such as the European Commission’s HORIZON Europe program. As an ethics advisor and trainer, he worked for the Austrian Medical Association, the Federal Chamber of Psychotherapists in Germany, and the Austrian Parliament.